1  fewer were ideal for guideline-based therapy, and absolute mortality remains high, suggesting the need for treatment str

2                                                  In Africa, mortality remains high because there is limited access to tre

3 sive therapies, the burden of recurrent ischemic events and mortality remains high, and future research is ongoing to pre

4  for acute respiratory distress syndrome (ARDS) exists, and mortality remains high.

5 fungal infections are common in critically-ill patients and mortality remains high despite antimicrobial therapy.

6 st two decades, yet gaps in the quality of care persist and mortality remains high.

7 y to improve, but the prognosis for the disease is poor and mortality remains high.

8 ensive clinical research to improve the management of ARDS, mortality remains high, and few strategies have shown a morta

9 ients with heart failure and reduced ejection fraction, but mortality remains high.

10  In rural India, as in many developing countries, childhood mortality remains high and the quality of health care availab

11                                             However, 30-day mortality remains high in these patients.

12  complication rates are generally low, although in-hospital mortality remains high.

13                                                    However, mortality remains high, at 8% in children and 15% in adults i

14 ve steadily improved in the past decade in Malawi; however, mortality remains high in specific subgroups.

15 ommon and lethal syndrome: although outcomes have improved, mortality remains high.

16 isk patients are selected for nonurgent transplant listing, mortality remains high, even among those who survive the init

17 ritically ill patients, and despite advances in management, mortality remains high.

18 ing malignant pleural mesothelioma with various modalities, mortality remains high, with median survival between 12 and 1

19                                                     Overall mortality remains high and mainly related with host factors.

20                                                  Short-term mortality remains high for elderly patients with acute myocar

21          Despite significant advances in care, however, the mortality remains high (30-100%).

22 mpirical inotropic therapy (with or without a vasodilator), mortality remains high.